Comparative Pharmacology
Head-to-head clinical analysis: APLENZIN versus TIAMATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APLENZIN versus TIAMATE.
APLENZIN vs TIAMATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bupropion is an aminoketone antidepressant that inhibits the reuptake of norepinephrine and dopamine, with no significant effect on serotonin. The exact mechanism of antidepressant action is unknown but is thought to be mediated by noradrenergic and dopaminergic pathways.
Tiamate is a combination of tiamulin (a pleuromutilin antibiotic) and valnemulin (a pleuromutilin antibiotic). Tiamulin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically at the peptidyl transferase center, preventing peptide bond formation. Valnemulin similarly binds to the 50S subunit and inhibits protein synthesis.
APLENZIN (bupropion hydrobromide) extended-release tablets: Initial dose 174 mg orally once daily in the morning; after 4 days, increase to 348 mg once daily. Maximum dose 348 mg/day.
250 mg orally twice daily
None Documented
None Documented
Mean terminal half-life of bupropion is 21 hours (SD ±9 hours). Steady state achieved within 8 days. Metabolites have longer half-lives: hydroxybupropion ~24 hours, threohydrobupropion ~37 hours, erythrohydrobupropion ~34 hours.
Terminal half-life 2–4 hours; dose adjustment needed in renal impairment (CrCl <30 mL/min)
Primarily renal (87% recovered in urine) with 10% fecal elimination. Unchanged bupropion accounts for <1% of renal excretion; metabolites (hydroxybupropion, threohydrobupropion, erythrohydrobupropion) predominate.
Primarily renal (70–80% as unchanged drug); biliary/fecal (20–30%)
Category C
Category C
Antidepressant
Antidepressant